Floatz logo

S-Gboxin

Diffuse Midline Glioma, H3 K27M-Mutant

Petrov, AndreyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the Diffuse Midline Glioma, H3 K27M-Mutant cohort.

Asset / SponsorPhaseRating
Ribociclib
Nationwide Children's Hospital
Phase 2B
Everolimus
Nationwide Children's Hospital
Phase 2CCC
Olutasidenib
Rigel Pharmaceuticals
Phase 2CCC
Pegargiminase
Sabine Mueller, MD, PhD
Phase 1/2CC
gsk1120212
St. Jude Children's Research Hospital
Phase 1CC

View all 14 →

Same molecule, other indications

S-Gboxin is also rated in:

giant cell glioblastomaDormant
CC
Indicative ·
43 / 100
View asset →
glioblastomaDormant
CC
Indicative ·
41 / 100
View asset →
gliosarcomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →